Fexeric

RSS

ferric citrate coordination complex

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

This marketing authorisation for Fexeric has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

This EPAR was last updated on 04/02/2020

Authorisation details

Product details
Name
Fexeric
Agency product number
EMEA/H/C/003776
Active substance
ferric citrate coordination complex
International non-proprietary name (INN) or common name
ferric citrate coordination complex
Therapeutic area (MeSH)
  • Hyperphosphatemia
  • Renal Dialysis
Anatomical therapeutic chemical (ATC) code
V03AE
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Akebia Europe Limited
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
23/09/2015
Contact address

c/o Matheson
70 Sir John Rogerson’s Quay
Dublin 2
Ireland

Product information

09/09/2019 Fexeric - EMEA/H/C/003776 - T/0015

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for treatment of hyperkalaemia and hyperphosphataemia

Therapeutic indication

Fexeric is indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD).

Assessment history

How useful was this page?

Add your rating
Average
1 rating